Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 6/20 | 0.66 |
| ▸ | GSK3B | P49841 | 6/20 | 0.66 |
| ▸ | AURKB | Q96GD4 | 5/20 | 0.66 |
| ▸ | PIM1 | P11309 | 5/20 | 0.66 |
| ▸ | GAA | P10253 | 4/20 | 0.54 |
| ▸ | MAPT | P10636 | 4/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | TUBB4A | P04350 | 5/20 | 0.53 |
| ▸ | TUBB | P07437 | 5/20 | 0.53 |
| ▸ | TUBA3C | P0DPH7 | 5/20 | 0.53 |
| ▸ | TUBA1B | P68363 | 5/20 | 0.53 |
| ▸ | TUBA4A | P68366 | 5/20 | 0.53 |
| ▸ | TUBB4B | P68371 | 5/20 | 0.53 |
| ▸ | TUBB3 | Q13509 | 5/20 | 0.53 |
| ▸ | TUBB2A | Q13885 | 5/20 | 0.53 |
| ▸ | TUBB8 | Q3ZCM7 | 5/20 | 0.53 |
| ▸ | TUBA3E | Q6PEY2 | 5/20 | 0.53 |
| ▸ | TUBA1A | Q71U36 | 5/20 | 0.53 |
| ▸ | TUBA1C | Q9BQE3 | 5/20 | 0.53 |
| ▸ | TUBB6 | Q9BUF5 | 5/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3668362 | 0.91 | AURKB (0.71) | ROCK2GSK3BAURKBPIM1GAA | |
| SCHEMBL3666498 | 0.89 | AURKB (0.64) | ROCK2GSK3BAURKBPIM1GAA | |
| SCHEMBL3636007 | 0.88 | TUBB4A (0.72) | ROCK2GSK3BAURKBPIM1GAA | |
| SCHEMBL3666928 | 0.83 | ROCK2 (0.62) | ROCK2GSK3BAURKBPIM1GAA | |
| SCHEMBL3634021 | 0.83 | ROCK2 (0.83) | ROCK2GSK3BAURKBPIM1GAA | |
| SCHEMBL20889527 | 0.83 | PIM1 (0.64) | ROCK2GSK3BAURKBPIM1DYRK3 | |
| SCHEMBL3668040 | 0.82 | ROCK2 (0.64) | ROCK2GSK3BAURKBPIM1GAA | |
| SCHEMBL1970288 | 0.79 | TUBB4A (0.68) | GAAMAPTSMN1; SMN2TUBB4ATUBB | |
| SCHEMBL3670033 | 0.79 | PIM1 (1.00) | ROCK2GSK3BAURKBPIM1GAA | |
| SCHEMBL3664701 | 0.77 | PIM1 (0.57) | ROCK2GSK3BAURKBPIM1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9163007-B2 | 5-substituted indazoles as kinase inhibitors | ABBVIE INC. (US) | 2015-10-20 | — | — | US | claimed |
| US-20140343066-A1 | 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-11-20 | — | — | US | claimed |
| US-20090203690-A1 | 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2009-08-13 | — | — | US | claimed |
| US-11530209-B2 | Small molecule inhibition of transcription factor SALL4 and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-12-20 | — | — | US | disclosed |
| US-20200317664-A1 | SMALL MOLECULE INHIBITION OF TRANSCRIPTION FACTOR SALL4 AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-10-08 | — | — | US | disclosed |
| WO-2019070943-A1 | SMALL MOLECULE INHIBITION OF TRANSCRIPTION FACTOR SALL4 AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-04-11 | — | — | WO | disclosed |
| US-9163007-B2 | 5-substituted indazoles as kinase inhibitors | ABBVIE INC. (US) | 2015-10-20 | — | — | US | disclosed |
| US-20140343066-A1 | 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-11-20 | — | — | US | disclosed |
| US-8648069-B2 | 5-substituted indazoles as kinase inhibitors | ABBVIE INC. (US) | 2014-02-11 | — | — | US | disclosed |
| EP-2167491-A1 | 5-HETEROARYL SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | Abbott Laboratories (US) | 2010-03-31 | — | — | EP | disclosed |
| US-20090203690-A1 | 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2009-08-13 | — | — | US | disclosed |
| WO-2008154241-A1 | 5-HETEROARYL SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2008-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140343066-A1 | 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | GSK3B, GSK3A, PIM3 | ROCK2 48/4885GSK3B 1/4885AURKB 125/4885 |
| US-20090203690-A1 | 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | GSK3B, GSK3A, PIM3 | ROCK2 48/4885GSK3B 1/4885AURKB 125/4885 |
| US-11530209-B2 | Small molecule inhibition of transcription factor SALL4 and uses thereof | SALL4, GLI2, TCF4 | ROCK2 3414/4885GSK3B 613/4885AURKB 2279/4885 |
| US-20200317664-A1 | SMALL MOLECULE INHIBITION OF TRANSCRIPTION FACTOR SALL4 AND USES THEREOF | SALL4, GLI2, TCF4 | ROCK2 3414/4885GSK3B 613/4885AURKB 2279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.